ReviewMolecular tools for assessing human depression by positron emission tomography
Introduction
Depression causes inner chaos and desperation that requires prompt attention and appropriate care. Success in discovering new, more effective antidepressant therapies may require detailed information on how molecules in the brain can cause and cure depressive disorders in humans. The living brain of humans can now be studied by positron emission tomography PET (Laruelle et al., 2002, Lammertsma, 2002), and that technology has become increasingly popular in psychiatric research. PET makes use of the radioactive decay of positron-emitting nuclides to derive an image of physiological and pharmacological events in a living organ such as the brain. Three types of studies characterize PET research in psychiatry, namely blood flow studies (Ravnkilde et al., 2003, Videbech et al., 2002, Fitzgerald et al., 2006), metabolic studies (Mayberg, 2003, Drevets et al., 2002), and molecular studies. Most molecular PET studies of human depression are based on the monoamine hypothesis (Schildkraut et al., 1968, Schildkraut and Kety, 1967), despite the need for exploring other strategies (Hindmarch, 2002, Berton and Nestler, 2006). The molecular tools for PET studies of human depression are positron-labeled compounds that can identify some aspect of neurotransmission (Fig. 1 and Table 1). This review presents a concise, factual account of PET studies that have used a molecular tool to assess some aspect of neurotransmission in the brain of depressed humans. Only articles published after 2002 are reviewed here (Table 2); excellent reviews of most molecular PET studies published before then are readily available elsewhere (Stockmeier, 2003, Smith et al., 2003, Hesse et al., 2004, Sheline et al., 2004, Meyer, 2007, Dunlop and Nemeroff, 2007, Kasper et al., 2002).
Section snippets
Serotonin synthesis
α-[11C]MTrp
Dopamine synthesis
[18F]Fluoro-L-dopa
Catecholaminergic neurotransmission
[11C]RTI-32
Histamine H1 receptor
[11C]Doxepin
Kano et al. used [11C]doxepin to test the notion that the histaminergic neuron system could be involved in human depression (Kano et al., 2004). They carried out PET scanning with [11C]doxepin in ten male patients with major depressive disorder and 10 healthy, age-matched males. The patients were allowed to take benzodiapines for insomnia and/or fluvoxamine for treatment of depression. PET data analysis used region-of-interest time–activity curves and an average arterial plasma
MAO type A
[11C]Harmine
Muscarinic type 2 receptor
[18F]FP-TZTP
Discussion
The complexity of both depression and PET provide a series of challenges for studying molecular mechanisms of depressive disorders in the living brain. Depression continues to plague populations allover the world, causing major suffering and economic burden. Depression consists of a variety of symptoms including hopelessness, sleep disturbance, altered appetite, lack of energy, concentration difficulties, low self-esteem, self-destructive behavior, painful bodily sensations, and suicidal
Role of the funding source
The authors are employed by the regional government of Middle Jutland that provides the finances required by the hospital-health system. The authors declare that, except for income received from our primary employer, no financial support has been received for preparing this review.
Contributors
Donald F. Smith and Steen Jakobsen
Conflict of interest
The authors declare that, except for income received from our primary employer, no financial support has been received for the writing of this review.
Acknowledgments
We thank everybody at the Center for Psychiatric Research and the PET Center of Aarhus University for providing a positive atmosphere in which to work.
References (72)
- et al.
Lack of effect of a single dose of hydrocortisone on serotonin(1A) receptors in recovered depressed patients measured by positron emission tomography with [11C]WAY-100635
Biol. Psychiatry
(2003) - et al.
Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis
Psychiatry Res.
(2007) - et al.
Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography
Biol. Psychiatry
(2006) - et al.
Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder
Biol. Psychiatry
(2007) - et al.
Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism
Eur. Neuropsychopharmacol.
(2002) - et al.
Serotonin-1A receptor imaging in recurrent depression: replication and literature review
Nucl. Med. Biol.
(2007) - et al.
An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression
Psychiatry Res.
(2006) - et al.
Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders
Neurosci. Biobehav. Rev.
(2004) Beyond the monoamine hypothesis: mechanisms, molecules and methods
Eur. Psychiatry
(2002)- et al.
Effects of repetitive transcranial magnetic stimulation on [11C]raclopride binding and cognitive function in patients with depression
J. Affect. Disord.
(2006)
Radioligand studies: imaging and quantitative analysis
Eur. Neuropsychopharmacol.
Positron emission tomography: imaging and quantification of neurotransporter availability
Methods
Positron emission tomography imaging in depression: a neural systems perspective
Neuroimaging Clin. N. Am.
Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography
Biol. Psychiatry
Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride
J. Affect. Disord.
Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study
Biol. Psychiatry
Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: an [(18)F] MPPF positron emission tomography study
Biol. Psychiatry
PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depression
J. Affect. Disord.
The dopamine hypothesis of reward: past and current status
Trends Neurosci.
Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter
J. Psychiatr. Res.
Brain serotonin1A receptor binding in major depression is related to psychic and somatic anxiety
Biol. Psychiatry
“Serotonin depression”—a biochemical subgroup within the affective disorders?
Science
An inventory for measuring depression
Arch. Gen. Psychiatry
New approaches to antidepressant drug discovery: beyond monoamines
Nat. Rev. Neurosci.
Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635
Mol. Psychiatry
Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907
Am. J. Psychiatry
5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB
Am. J. Psychiatry
Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB
Mov Disord.
Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder
Arch. Gen. Psychiatry
Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [(11)C]NNC-112
Neuropsychopharmacology
Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan
Arch. Gen. Psychiatry
Decreased striatal D1 binding as measured using PET and [11C]SCH 23,390 in patients with major depression with anger attacks
Depress. Anxiety.
The role of dopamine in the pathophysiology of depression
Arch. Gen. Psychiatry
A rating scale for depression
J. Neurol. Neurosurg Psychiatry
Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635
Int. J. Neuropsychopharmacol.
Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain
J. Cereb. Blood Flow Metab.
Cited by (32)
High-dose testosterone treatment increases serotonin transporter binding in transgender people
2015, Biological PsychiatryCB1 receptor-deficient mice as a model for depression
2012, NeuroscienceCitation Excerpt :These features let that the 5-HT neurons may modulate a large population of neurons in the brain. The impairment of serotonin neurotransmission has been classically associated to the pathophysiology of mood disorders and depression (Holmes et al., 2003; Smith and Jakobsen, 2009; Mann and Currier, 2010). Most of antidepressant compounds are based on molecules that target a single the serotonin transporter in the brain (Celada et al., 2004).
Chronic stress is linked to 5-HT<inf>1A</inf> receptor changes and functional disintegration of the limbic networks
2011, NeuroImageCitation Excerpt :We find this unlikely, not only since the results did not change when the calculations were restricted to those subjects with normal MADRAS scores, but also because the BP was similar among patients with normal and elevated scores, and no interaction with MADRAS was found. According to a recent meta analysis, normal, reduced, and elevated 5-HT1A receptor bindings have all been found in depressed subjects (Smith and Jakobsen, 2009). Furthermore, when detected, the changes do not seem to be restricted to the limbic structures (Drevets et al., 1999; Sargent et al., 2000).
MRI/PET Brain Imaging
2020, PET and SPECT in NeurologyThe rise and fall of MRI studies in major depressive disorder
2019, Translational PsychiatryNeuroimaging Advance in Depressive Disorder
2019, Advances in Experimental Medicine and Biology